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Summary
Objective: IL-1 plays a fundamental role in osteoarthritis (OA) pathophysiology and cartilage destruction. Targeting the activation
mechanism of this cytokine appears to be important as a therapeutic approach. As the interleukin-1 converting enzyme (ICE) is the
physiologic modulator of the production of active IL-1, we investigated the effect of diacerhein and its active metabolite rhein used in the
treatment of OA patients, on the enzyme expression and synthesis on human OA cartilage. Further, we looked at the effect of both drugs on
the production of the active form of IL-1 and IL-18.
Methods: The expression and synthesis of ICE were investigated on human OA cartilage explants using in-situ hybridization and
immunohistochemical methods, respectively. The effect of the drugs on ICE OA chondrocytes was also determined by Northern blotting and
a specific ELISA assay. Furthermore, the effect of both drugs on the level of active IL-1 and IL-18 was examined by immunohistochemistry.
Results: Data showed that diacerhein and rhein have no true effect on reducing total ICE mRNA by both Northern blotting analysis and in-situ
hybridization. A marked and statistically significant decrease was, however, found for protein production. ELISA showed a reduction of 31%
(P<0.04) for diacerhein and 50% (P<0.02) for rhein. The drugs’ immunohistological cell score reduction was similar to data from the ELISA,
and a statistical significant reduction of ICE production was found at both superficial and deep zones of the cartilage. IL-1 and IL-18 were
both preferentially produced in chondrocytes of the superficial zone. For each of these cytokines, both drugs demonstrated a statistically
significant decrease in this zone. A marked decrease was also noted in the deep zone, but statistical significance was reached only for rhein.
Conclusion: These results provide a novel regulatory mechanism by which diacerhein and rhein could exert a down-regulation on IL-1’s effect
on OA cartilage. © 2000 OsteoArthritis Research Society International
Key words: OA cartilage, Diacerhein, ICE, Interleukin-1, Interleukin-18.Received 17 August 1999; accepted 19 November 1999
This study was supported by a grant from Negma-Steba Inter-
national Development N.V., The Hague, Netherlands.
Address correspondence and reprint requests to: Johanne
Martel-Pelletier, PhD, Osteoarthritis Research Unit, Centre hospi-
talier de l’Universite´ de Montre´al (CHUM), Hoˆpital Notre-Dame,
1560 rue Sherbrooke Est, Y-2622 Pavillon De Se`ve, Montre´al,
Que´bec, Canada H2L 4M1. Tel: 514-281-6000, ext. 6658; Fax:
514-896-4680.Introduction
Osteoarthritis (OA) is a multifactorial disease characterized
by a progressive degradation of articular cartilage. Articular
cartilage is an avascular tissue in which the chondrocytes
are embedded in an abundant extracellular matrix, com-
posed mainly of type II collagen, aggrecans, glycoproteins
and other minor components. The integrity of the tissue
structure is maintained by a balanced control between
anabolic and catabolic processes, which is regulated by
ambient growth factors and cytokines.
Numerous studies from either in-vitro or in-vivo exper-
iments have established the key role of IL-1 in the OA
process.1–7 Several cells including macrophages, synovial
cells and chondrocytes in articular joint tissues produce
IL-1. This cytokine contributes to the degeneration of
articular cartilage by stimulating the cells to produce
proteolytic enzymes (in cartilage, the most important are186the metalloproteases—collagenases, stromelysins and
gelatinases), but also by decreasing the anabolism of the
chondrocytes (see review8).
IL-1 is synthesized as a biologically inactive precursor
and requires a proteolytic cleavage to be active.9–11 This is
achieved by a highly selective protease, the IL-1 converting
enzyme (ICE), also called caspase-1.12,13 This enzyme,
ICE, has another cytokine as a specific substrate, the IL-18
or interferon gamma inducer.14,15 IL-18 has structural simi-
larities to the IL-1 protein family and is produced as a
pro-cytokine.16,17 ICE is an endopeptidase localized intra-
cellularly. This enzyme is synthesized as a 45 kDa pro-
enzyme and the conversion into an active form involves
autoproteolysis.13,18 The active enzyme is formed as an
heterodimer composed of two subunits of 20 and 10 kDa,
both of which are required for catalytic activity.19–21
Our laboratory has recently shown that ICE is expressed
and synthesized by both human synovial membrane and
cartilage, with a marked increase in OA tissues over
normal.22 In OA cartilage, ICE appears to play a crucial role
in IL-1 and IL-18 maturation, as ex-vivo treatment of
cartilage explants with a specific ICE inhibitor (YVAD)
completely abrogated the production of active IL-1 and
markedly reduced the production of IL-18.22 These find-
ings, combined with others showing that transgenic ICE-
deficient mice had major defects in the production of
mature IL-1 and IL-18.23,24 give credence to the use of
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diseases, including OA.
Diacerhein is a drug belonging to the anthraquinone
chemical class and employed in OA treatment. This drug is
a low molecular weight heterocyclic compound designated
as 4,5-bis (acetyloxy)-9,10-dioxo-2 anthracene) carboxylic
acid. Its mechanism of action appears to be different
from that described for a classical nonsteroidal anti-
inflammatory drug, in which diacerhein and its active
metabolite rhein inhibit IL-1 production and activity and,
depending on the cell type, either did not affect prosta-
glandin synthesis (macrophages) or stimulated its syn-
thesis (chondrocytes).25–31 In animal models of OA,
diacerhein has demonstrated protective effects on cartilage
matrix degradation.32–35 In clinical trials, its oral admin-
istration was associated with symptomatic improvement in
the majority of patients with OA.36–38
As IL-1 plays a fundamental role in OA pathophysiology
and cartilage destruction, targeting the activation mechan-
ism of this cytokine appears to be of importance as a
therapeutic approach. As ICE is the physiologic modulator
of the production of active IL-1, we first investigated the
effect of diacerhein and rhein on this enzyme’s expression
and synthesis on human OA cartilage. Secondly, we looked
at the effect of both drugs on the production of the active
forms of IL-1 and IL-18.Material and methods
SPECIMEN SELECTION
Cartilage specimens (tibial plateaus) were obtained from
OA patients (12F/7M; 72±7 mean age±SD) undergoing
total knee joint replacement. The diagnosis was estab-
lished according to the American College of Rheumatology
criteria.39 The specimens were obtained under aseptic
conditions and processed as previously described.22,40
Briefly, the cartilage was dissected from the underlying
bone. Areas of fibrocartilage were identified and excluded.
In a first set of experiments, cartilage explants (about
100 mg) were dissected, rinsed in cold saline solution, and
incubated for 24 h at 37°C in a humidified atmosphere of
5% CO2/95% air in medium containing Dulbecco’s modified
Eagle’s medium (DMEM; Gibco-BRL Canadian Life
Technologies, Burlington, Ontario, Canada), 2.5% heat-
inactivated fetal calf serum (FCS; Hyclone, Logan, UT),
antibiotics (penicillin, 100 U/ml; streptomycin 100 g/ml;
Gibco-BRL), in the presence or absence of 20 g/ml of
diacerhein or rhein (Negma Laboratories, Tossus Le Noble,
France). The dosage use is within the range of physio-
logical blood levels measured in patients treated with
diacerhein.41 Following the incubation, cartilage specimens
were processed for either in-situ hybridization or immuno-
histochemistry.
In another set of experiments, chondrocytes were
released from the cartilage by sequential enzymatic diges-
tion as described:22,30 1 h with 2 mg/ml pronase followed
by 6 h with 1 mg/ml collagenase (type IV, Sigma, St. Louis,
MO) at 37°C in DMEM with 10% FCS and antibiotics. The
digested tissue was centrifuged and the pellet washed. The
isolated chondrocytes were seeded at high density in tissue
culture flasks and cultured in DMEM supplemented with
10% FCS and antibiotics at 37°C in a humidified atmos-
phere. At confluence, the cells were detached and pas-
saged once, then seeded at high density in the required
flasks, and were allowed to grow for 5 days in DMEMsupplemented as above. The culture medium was changed
every second day and, 24 h before the experiment, the
cells were incubated in fresh medium containing 2.5%
FCS. Chondrocytes were then incubated with 20 g/ml of
diacerhein and rhein. Following the 24-h incubation period,
cells were processed for mRNA or protein determinations
(see below).ICE EXPRESSIONRNA extraction and Northern blotting
Total RNA was extracted from chondrocytes using the
Trizol reagent (Gibco-BRL) as previously described,22,42
and processed according to the manufacturer’s specifica-
tions. The extracted RNA was quantitated spectrophoto-
metrically. For Northern blot, 20 g of total RNA was
resolved on 1.2% formaldehyde-agarose gels and trans-
ferred electrophoretically to nylon membranes (Hybond-N;
Amersham Pharmacia Biotech, Oakville, Ontario, Canada)
in a 10 mM sodium acetate buffer (pH 7.8) containing
20 mM Tris and 0.5 mM EDTA overnight at 4°C. The
RNA was cross-linked to the membranes by exposure to
ultraviolet light.
The human ICE probe was as previously described.22
The primers were: 5′-GTTCCATGGGTGAAGGTACA-3′
(sense) corresponding to position 44–63 bp of the
published sequence of the human gene;43 and
5′-AATGAGAGCAAGACGTGTGC-3′ (antisense) from
position 482–501 bp. Using these primers, a 456 bp frag-
ment was obtained and cloned directly into the pCRII vector
(Invitrogen, San Diego, CA).In-situ hybridization
Cartilage specimens were processed as previously
described22 using ICE RNA probe labeled with digoxigenin-
UTP (DIG-UTP, Boehringer Mannheim, Indianapolis, IN).
Briefly, cartilage samples were fixed in 4% paraformalde-
hyde and embedded in paraffin. Five micron sections were
deparaffinized, hydrated, incubated in 0.3% Triton X100/
PBS and digested using 0.1% pepsin (Boehringer
Mannheim) in 0.2 M HCl, and 10 g/ml proteinase-K
(Sigma) in 100 mM Tris-HCl and 50 mM EDTA pH 8. Each
slide was rinsed with 0.1% glycine/PBS (pH 7.4. 22°C), and
post-fixed in 4% paraformaldehyde for 5 min. Slides were
acetylated with 0.25% acetic anhydride in 0.1 M trieth-
anolamine pH 8, then immersed in prehybridization buffer:
50% deionized formamide with Dower® MR, 1× Denhardt’s
solution, 0.5% denatured salmon sperm DNA, 0.25% yeast
tRNA and 5% dextran sulfate (all from Sigma). The slides
were then rinsed with 2×SSC and hybridized with the
DIG-labeled RNA-antisense probe (or DIG-labeled RNA-
sense probe for controls) at 1 g/ml in the prehybridization
buffer. Following overnight incubation with the probe at
46°C, the slides were washed and digested with 20 g/ml
RNase-A (Sigma) for 30 min at 37°C. After washing in SSC,
the cartilage specimens were processed using the anti-DIG
POD Fab fragments (1.5 U/ml; dilution 1/100; Boehringer
Mannheim) and the color was developed by 3′-3′
diaminobenzidine (DAB; Dako Diagnostics Canada Inc.,
Mississauga, Ontario, Canada) and hydrogen peroxide.
Slides were counterstained with nuclear fast red stain
(Digene Diagnostics, Silverspring, MD). All specimens
were examined on a Leitz periplan photomicroscope, and
micrographs taken using Kodak Ektachrome 64 color film.
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performed using our previously published methods.22,40,44
The expression of ICE was estimated by determining the
number of cells staining positive within the different layers
of tissue. For each specimen, six microscopic fields were
examined (×40; Leitz Diaplan): three fields at the super-
ficial and upper intermediate layers (superficial zone), and
three fields at the lower intermediate and deep layers (deep
zone). The total number of chondrocytes and the number of
chondrocytes staining positive for ICE using the antisense
probe were evaluated separately for each zone of cartilage
and for the full-thickness cartilage (superficial and deep
zones). Each slide was subjected to a double-blind evalu-
ation, with a maximum variation of 5% recorded. Results
were determined by the percentage of chondrocytes stain-
ing positive for ICE (cell score), the maximum score being
100%.
The ICE RNA probe was constructed as detailed in the
RNA extraction and Northern blotting section, transcribed,
labeled with the DIG-11-UTP, and revealed using a
22luminescent reagent.ICE PROTEIN DETERMINATIONICE ELISA
For the quantitative determination of human ICE in
chondrocytes, an ELISA kit from Cistron Biotechnology
(Pine Brook, NJ) was used. After being isolated, chondro-
cytes were incubated for 24 h in the absence or presence
of diacerhein and rhein at 10 and 20 g/ml. After washing
with ice-cold PBS, the chondrocytes were scraped and
resuspended in a lysis buffer (10 mM Tris-HCl, 5 mM
CaCl2, 0.25% Triton X-100, 1 mM PMSF, 10 g/ml pep-
statin, 10 g/ml leupeptin, pH 7.5). This ELISA is a mono-
clonal polyclonal based assay that is specific for the p20
subunit and recognizes both the precursor and active forms
of ICE. The antiserum used in this assay showed specificityto human ICE, and no cross-reactivity was found with the
cytokines, such as IL-1 and caspase-3, -7 or -8.Fig. 1. Representative Northern blot of OA chondrocytes incubated in the absence (control) or presence of diacerhein and rhein at 20 g/ml.
The ratio indicates the mean±SEM of three independent experiments, and refers to the relative expression of ICE mRNA after being
normalized to GAPDH. mRNA extracted from the human monocyte cell line THP-1 is also represented.Immunohistochemistry
Cartilage specimens were processed for immunohisto-
chemistry as previously described.22,40,44 Specimens were
fixed in 4% paraformaldehyde and embedded in paraffin.
Sections (5 ) of paraffin-embedded specimens were
deparaffinized in toluene, dehydrated in a graded series of
ethanol, and preincubated at 65°C for 20 min in 10 mM
sodium citrate buffer pH 6.0 (when using ICE antibody) or
with chondroitinase ABC (0.25 U/ml in PBS; Sigma) for
60 min at 37°C (when using IL-1 and IL-18 antibodies).
Slices were then washed in PBS, followed by 0.3% hydro-
gen peroxide/methanol. They were further incubated with
2% normal serum (Vector Laboratories, Burlingame, CA)
and overlaid with the antibodies for 18 h at 4°C in a
humidified chamber. The evaluation of chondrocytes stain-
ing positive was performed as detailed above for in-situ
hybridization.
The antibody used for ICE was an affinity-purified rabbit
polyclonal antibody raised against a peptide corresponding
to epitope 2-20 mapping at the caraboxy terminus of the
ICE precursor of human origin and termed P20 subunit
(#sc-1780; 10 g/ml; Santa Cruz Biotechnology Inc., Santa
Cruz, CA). This antibody recognizes both the precursor and
active forms of ICE. The IL-1 antibody used was a
monoclonal anti-human IL-1 (#MAB201, 10 g/ml; R&D
Systems Inc., Minneapolis, MN) that recognizes the mature
(active) form of IL-1 and shows only minimal cross-
reactivity with pro-IL-1 in biological fluid. The IL-18 anti-
body used was a goat polyclonal raised against a peptide
corresponding to the amino acids 175-193 mapping at the
carboxy terminus of the IL-18 precursor (#sc-6177, 5 g/ml;
Santa Cruz). This antibody recognizes both the precursor
and active forms of IL-18, and has no cross-reactivity with
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probe. (C, D) represent OA cartilage treated with diacerhein (C) or rhein (D) at 20 g/ml. In-situ hybridization was carried out using an ICE
mRNA antisense probe labeled with dDIG-11-UTP. (Original magnification ×63.) (E) Histogram of the cell score for ICE mRNA in OA cartilage
from the superficial (superficial and upper intermediate layers) and deep (lower intermediate and deeper layers) zones. Data are expressed
as the mean±SEM cell score. Statistical analysis revealed a significance difference (P<0.001) between the OA controls from the superficial
and deep zones.
190 F. Moldovan et al.: Diacerhein reduced ICE production in OA cartilageother interleukins (Santa Cruz), and more specifically with
IL-1 (personal observation).
Each slide was washed three times in PBS, pH 7.4, and
stained using the avidin-biotin complex method (Vectastain
ABC kit; Vector Laboratories). The color was developed by
the DAB (Dako Diagnostics) containing hydroxide peroxide
and the slides counterstained with nuclear fast red stain
(Digene Diagnostics Inc.). The counterstaining gives light
pink-stained nuclei, and specific staining appears as
brown-stained cytoplasm.
To determine specificity of staining, three controls were
used: (i) adsorbed immune serum (1 h, 37°C) with 10-fold
molar excess of the specific peptides for the ICE antibodies
(#sc-1780 P; Santa Cruz), the rhIL-1 (Genzyme,
Cambridge, MA) and rhIL-18 (Santa Cruz); (ii) omission of
the primary antibody; and (iii) substitution of the primary
antibody with IgG (Nordic Immunology, Tilburg, The
Netherlands) following the same experimental protocol.STATISTICAL ANALYSIS
The data are expressed as a mean±SEM. Statistical
significance was assessed by the paired Student’s t-test,
and P<0.05 was considered significant.ResultsEFFECT OF DIACERHEIN AND RHEIN ON ICE EXPRESSION
The effect of the drugs on ICE mRNA levels was first
examined on OA chondrocytes using Northern blotting
analysis (N=3). Generally, on these cells only one tran-
script of 1.9 kb is detected. When a very high level of ICE
mRNA is present, a second transcript of 2.5 kb could beseen. As illustrated in Fig. 1, diacerhein and rhein at
20 g/ml has no true effect on ICE mRNA levels.
Since the Northern blotting reflects the level of expres-
sion in chondrocytes from the whole cartilage population,
further experiments using in-situ hybridization were then
performed permitting the cellular localization of ICE expres-
sion. Results (N=7) revealed, as expected,22 that in OA,
ICE is expressed throughout the entire cartilage thickness,
with a greater number of chondrocytes staining positive in
the superficial zone compared with the deep zone; percent-
ages of 36.4±5.0% and 21.3±5.8% (P<0.001) were found
respectively (Fig. 2). Both diacerhein and rhein only slightly
decreased cell scores, with a higher effect at the superficial
zone (Fig. 2). However, this did not reach statistical
significance.Fig. 3. ICE protein determination in human OA chondrocytes using a specific ELISA assay. Cells were incubated in the absence (control) or
presence of diacerhein or rhein at 20 g/ml and 10 g/ml. Data are expressed as the mean±SEM cell score. P-values indicate comparison
with the OA control.EFFECT OF DIACERHEIN AND RHEIN ON ICE SYNTHESIS
Data from the specific ICE ELISA assay (N=6) revealed
that OA chondrocytes produced a large amount of this
enzyme (246.9±27.2 pg/5×105 cells). Diacerhein and
rhein, at both concentrations used (20 and 10 g/ml)
induced a statistically significant decrease in ICE protein
levels (Fig. 3). A mean reduction of about 34% was found
for diacerhein and 45% for rhein.
According to a previous immunohistochemical study,22 a
statistically higher percentage of chondrocytes stained
positive for ICE protein at the superficial zone than at the
deep zone. As illustrated in Fig. 4, results from this study
agreed with the previous ones in which a statistically
significant greater (P<0.02) number of positive cells were
found in the superficial zone (Fig. 4). Diacerhein and rhein
(N=7) induced a marked and statistically significant
decrease in the number of cells staining positive for ICE.
Osteoarthritis and Cartilage Vol. 8 No. 3 191This effect was found for both the superficial and deep
zones of the cartilage.Fig. 4A–D.EFFECT OF DIACERHEIN AND RHEIN ON ACTIVE IL-1 AND IL-18
PRODUCTION
Additional experiments were carried out to evaluate the
effects of both agents on ICE toward its specific substrates,
IL-1 and IL-18. Both IL-1 and IL-18 were detected in all
OA cartilage specimens examined (N=7).
In the untreated cartilage, staining for IL-1 was found
predominantly in chondrocytes at the superficial zone. In
this zone, 9.5±1.4% of the cells were immunoreactivecompared to 2.1±0.8% (P<0.0001) in the deep zone (Fig.
5). The diacerhein- and rhein-treated cartilage showed a
marked decrease in the number of chondrocytes staining
positive for IL-1 regardless of the cartilage zones. In the
superficial zone, a significant reduction in the cell score
was found when treated cartilage was compared to control
(untreated) (diacerhein, P<0.009; rhein, P<0.003). A signifi-
cant reduction (P<0.01) was also found for rhein-treated
cartilage at the deep zone.
Immunostaining for IL-18 demonstrated a cellular distri-
bution pattern similar to that described for IL-1. However,
a larger number of chondrocytes stained positive for IL-18
when compared with IL-1. Cell scores of 40.9±4.6% and
21.4±3.1% (P<0.0005) were found at the superficial and
192 F. Moldovan et al.: Diacerhein reduced ICE production in OA cartilagedeep zones respectively (Fig. 5). Both diacerhein and rhein
induced a significant (P<0.02, P<0.04 respectively) reduc-
tion of IL-18 production at the superficial zones, and for
rhein (P<0.009) in the deep zones.Discussion
Morphological changes observed in OA include cartilage
erosion and varying degrees of synovial inflammation.8 It is
known that proinflammatory cytokines, locally produced by
pathological articular joint tissues, contribute to these
alterations. Studies on the contribution of cytokines to the
cartilage destruction in OA, however, point to a prime role
played by IL-1.1–7 Perpetuation of the degradative pro-
cess in articular joint tissue appears, at least in part,
dependent on the level of the active cytokine. Therefore
IL-1 activity represents an important therapeutic target.
IL-1 is synthesized as a precursor that undergoes
proteolytic cleavage by ICE, permitting the activated
cytokine to exit the cell. The potential role of ICE in several
pathophysiological systems has been the focus of much
attention in the last few years. Several in-vitro, and particu-
larly in-vivo studies using ICE deficient mice have demon-
strated that this enzyme plays a key role in the maturation
(activation) process of IL-1 but also in another cytokine,
IL-18.14–17 Hence, in vivo, the action of ICE on these
cytokines appears to be a key limiting factor for these
cytokines to be secreted by the cell.
Results from several studies have shown that diacerhein
and rhein are potent inhibitors of proinflammatory cytokinesynthesis and activity, particularly for IL-1.29,31 Moreover,
in vitro diacerhein and rhein demonstrated their ability to
inhibit IL-1-induced collagenase synthesis by chondro-
cytes, the IL-1-induced NO production and to partially
reverse the IL-1-induced inhibition of proteoglycan
synthesis.26–28,30 We hypothesize that the effect on IL-1
could have occurred through, at least in part, the matur-
ation process involving the inhibition of ICE. Our data
showed that diacerhein and rhein markedly inhibit ICE
production as well as the activation processing of IL-1 and
IL-18 in vitro in chondrocytes and ex vivo in cartilage
explants.
Our laboratory previously observed the presence of a
significant up-regulation of ICE, IL-1 and IL-18 in human
OA cartilage.22 The present finding of an inhibition of ICE
by drugs is of particular importance, since ICE is known to
have a pivotal role in the maturation process of IL-1 in OA
cartilage, one of the cytokines believed to play a predomi-
nant role in the progression of the disease’s structural
changes. The up-regulation of ICE levels in OA tissues was
demonstrated to be present both at the synovial membrane
and cartilage.22 In the synovium, the concomitant increase
in the expression of ICE and active IL-1 favors an import-
ant role of ICE as one of the main mechanisms by which
excess production of mature IL-1 can occur. IL-1 could
then, in an autocrine/paracrine fashion, exert its local
effects on OA cells by inducing an excess in production of
proteases, nitric oxide and other catabolic factors respon-
sible for joint structural damages. At the cartilage level, the
simultaneous increase in production of both IL-1 and ICEFig. 4. Representative sections of ICE immunostaining in human OA cartilage specimens (A). (B) represents the immunohistology done on
cartilage incubated with the adsorbed immunoserum as control. In (C) and (D), OA cartilage was treated with diacerhein (C) or rhein (D) at
20 g/ml. (Original magnification ×63.) (E) Histogram of ICE immunostaining score in human OA cartilage from the superficial (superficial
and upper intermediate layers) and deep (lower intermediate and deeper layers) zones. Data are expressed as the mean±SEM cell score.
Statistical analysis revealed a significant difference (P<0.02) between the OA controls from the superficial and deep zones, and P-values
indicate comparison with the OA control.
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ICE is a key factor responsible for the local increase in the
level of mature IL-1 in this tissue.
The action of diacerhein and its active metabolite rhein
did not appear to occur through the reduction of total ICE
mRNA. Another possibility, although speculative, is that
these drugs could act on ICE mRNA half-life. Yet, this was
not demonstrated in any of the factors affected by
diacerhein/rhein. In this study, however, we showed that
these drugs reduce ICE production. By immunohistochem-
istry, the reduction of ICE protein levels in OA cartilage was
found both at the superficial and deep zones, demonstrat-
ing a good diffusion of the drugs in the matrix and also
suggesting a similar sensitivity of the chondrocytes fromboth zones to the drug. This study and previous reports
clearly demonstrate that diacerhein and rhein are very
potent agents to reduce in vitro the action played by the
IL-1 system in OA cartilage. The in-vivo effect of diacerhein
on the IL-1 system is therefore several-fold, since this drug
inhibited the global synthesis of IL-1, its maturation, and
the IL-1 receptor levels on OA cells.29 Consequently, di-
acerhein could produce in vivo a complete inhibition of the
IL-1 effect. It is therefore not surprising that, in vivo,
diacerhein was shown to reduce the severity of morpho-
logical changes in the experimental dog model of OA, since
IL-1 has been shown to play a predominant role in the
progression of the structural changes.4,45,46 In the matter
of diacerhein being a potential disease-modifying effector, itFig. 5. Histogram of the immunostaining score for IL-1 (top panel) and IL-18 (bottom panel) in OA cartilage from the superficial (superficial
and upper intermediate layers) and deep (lower intermediate and deeper layers) zones when human OA cartilage were incubated in the
absence (control) or presence of diacerhein or rhein at 20 g/ml. Data are expressed as the mean±SEM cell score. Statistical analysis
revealed a significant difference between the OA controls from the superficial and deep zones for IL-1 (P<0.001) and IL-18 (P<0.005), and
P-values indicate comparison with the OA control.
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